Kevin Kaster, J.D.

Mr. Kaster has over 25 years of experience in both smaller biotechnology firms and large pharmaceutical companies. He has an impressive track record of developing effective patent and licensing strategies for important technologies and drug products. Mr. Kaster was formerly the VP Intellectual Properties at Kosan Biosciences, which had geldanamycin and epothilone anti-cancer agents in its pipeline and was acquired by Bristol-Myers Squibb in 2008. Prior to Kosan, he was the VP of Intellectual Property at Geron Corporation. Geron owns rights in telomerase and human embryonic stem cell technologies. Prior to Geron, he was Director of Intellectual Property at Affymax and a Senior Patent Attorney at Cetus Corporation. Mr. Kaster began his career at Eli Lilly and Company, first as a research scientist and then as a patent technician. He received his law degree from Indiana University School of Law - Indianapolis and his Bachelor of Science degree magna cum laude from Vanderbilt University in Chemistry.


Homer Pearce, Ph.D.

Dr. Pearce recently retired from Lilly Research Laboratories where he served as Vice President of Cancer Research and Clinical Investigation and Distinguished Research Fellow. Dr. Pearce has more than 27 years of experience in cancer drug discovery and was involved in the development of more than 25 investigational drugs which entered clinical trials for cancer, of which three have resulted in regulatory approvals and others are still in development. These drugs, which include Gemzar and Alimta, achieved 2007 combined worldwide sales exceeding $2 billion. His work included the use of natural products as models to identify new leads for cancer drug discovery and new efforts to probe mechanisms of drug resistance. He has been a consultant to the National Cancer Institute and the American Cancer Society and is a member of the editorial board of the Journal Molecular Cancer Therapeutics. Dr. Pearce received his Ph.D. in chemistry from Harvard.


Paul S. Anderson, Ph.D.

Paul Anderson is a retired pharmaceutical industry expert; former VP at Bristol-Myers Squibb, VP of Chemistry at Merck's West Point, PA facility, and senior VP for DuPont Pharmaceuticals. He has been involved in research leading to the approved drugs Zocor, Trusopt, Aggrastat, Crixivan and Sustiva. Dr. Anderson is the 2006 Priestley Medalist, the highest honor granted by the American Chemical Society. He is also the recipient of numerous awards including the E.B. Hershberg Award for important discoveries in medicinally active substances. He was named the 2002 recipient of the Perkin Medal; the highest honor given for outstanding applied Chemistry in the United States. Dr. Anderson obtained B.S. in Chemistry from the University of Vermont and Ph.D. in Chemistry from the University of New Hampshire.